- Home
- SISI vs RLYB Comparison
SISI vs RLYB Comparison
Compare SISI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- RLYB
- Stock Information
- Founded
- SISI 1997
- RLYB 2018
- Country
- SISI China
- RLYB United States
- Employees
- SISI N/A
- RLYB N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- RLYB Health Care
- Exchange
- SISI Nasdaq
- RLYB Nasdaq
- Market Cap
- SISI 14.9M
- RLYB 13.3M
- IPO Year
- SISI 2016
- RLYB 2021
- Fundamental
- Price
- SISI $0.72
- RLYB $0.31
- Analyst Decision
- SISI
- RLYB Hold
- Analyst Count
- SISI 0
- RLYB 4
- Target Price
- SISI N/A
- RLYB $15.00
- AVG Volume (30 Days)
- SISI 1.1M
- RLYB 81.0K
- Earning Date
- SISI 05-27-2025
- RLYB 05-08-2025
- Dividend Yield
- SISI N/A
- RLYB N/A
- EPS Growth
- SISI N/A
- RLYB N/A
- EPS
- SISI N/A
- RLYB N/A
- Revenue
- SISI $11,072,553.00
- RLYB $848,000.00
- Revenue This Year
- SISI N/A
- RLYB N/A
- Revenue Next Year
- SISI N/A
- RLYB N/A
- P/E Ratio
- SISI N/A
- RLYB N/A
- Revenue Growth
- SISI 145.88
- RLYB N/A
- 52 Week Low
- SISI $0.39
- RLYB $0.22
- 52 Week High
- SISI $117.65
- RLYB $2.00
- Technical
- Relative Strength Index (RSI)
- SISI 42.76
- RLYB 41.15
- Support Level
- SISI $0.56
- RLYB $0.29
- Resistance Level
- SISI $0.79
- RLYB $0.32
- Average True Range (ATR)
- SISI 0.13
- RLYB 0.02
- MACD
- SISI -0.01
- RLYB 0.01
- Stochastic Oscillator
- SISI 18.40
- RLYB 50.00
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.